Industry News

FedEx package containing a check for $3,000, which you're urged to deposit..."/>
R.I. Department of Labor warns of scam found on EmployRI job board [The Providence Journal, R.I.]
Sun Pharmaceutical Industries Ltd on Thursday said it has entered into a licensing agreement with Barcelona-based Almirall SA for the development and commercialization of tildrakizumab, a drug to treat chronic immune disease psoriasis, in Europe. Under the terms of the licence agreement, Almirall will pay Sun Pharma an initial payment of $50 million, Sun Pharma said in a statement. In addition, Sun Pharma will be eligible to..."/>
Sun Pharma enters licensing pact with Almirall to market psoriasis drug in Europe [Mint, New Delhi]
Angle PLC. For immediate release 28 July 2016. USE OF PARSORTIX IN GANNET53 DRUG TRIAL IN OVARIAN CANCER."/>
ANGLE plc: Use of Parsortix in GANNET53 Drug Trial
Angle PLC. For Immediate Release 28 July 2016. Preliminary Results for the year ended 30 April 2016."/>
Angle PLC: Preliminary Results
Ipsen’s First Half 2016 Results
Lupin Ltd, India's third largest drug maker on Wednesday said its US unit Lupin Pharmaceuticals Inc. has received preliminary approval from the US drug regulator to market a generic equivalent of GlaxoSmithKline Plc's ViiV Healthcare's antiretroviral Lexiva tablets in 700 milligram dosage form. Lexiva generically called fosamprenavir calcium tablets is used with other antiretroviral agents for the treatment of HIV-1 infection."/>
BRIEF: Lupin gets preliminary nod for generic HIV drug Lexiva in US [Mint, New Delhi]
Mylan NV is divesting two generic drugs to resolve anticompetition concerns from U.S. regulators that its acquisition of Swedish specialty drugmaker Meda AB would have led to higher prices for the medicines. With U.S. clearance for the $7.2 billion deal, Mylan said it has received all required government approvals for the acquisition. Mylan, which is based in the Netherlands and run from offices in Cecil, agreed to sell the rights and assets related to generic felbamate, a..."/>
Mylan to divest two generic drugs to win antitrust clearance for Meda acquisition [The Pittsburgh Tribune-Review]
Tactile Systems Technology Inc. has lowered the proposed share price for an initial public offering in hopes of completing the process. In an amended filing with the Securities and Exchange Commission on Wednesday, the company, operating as Tactile Medical, lowered the proposed offering price to $10 per share. At $10 per share, the Minneapolis company could raise as much as $46 million, if underwriters exercise their overallotment."/>
Tactile Systems lowers IPO offering price [Star Tribune (Minneapolis)]
Abbott Laboratories' pursuit of Alere, a health care diagnostics company, may have been a bad idea. Alere faces a federal criminal investigation over its Medicare and Medicaid billing practices, according to a report by the Wall Street Journal. News of the inquiry sent Alere's shares plunging nearly 29 percent Wednesday to $31.47 on the New York Stock Exchange."/>
BRIEF: Abbott has more reason to walk away from Alere deal [Chicago Tribune]
Chromadex built the first ever testing program that covers supply chain, ingredient testing, and product verification at the..."/>
BPI Sports Expands Third Party-Testing and Quality Verification to BEST CREATINE™ and BEST BCAA™
Tactile Systems Technology, Inc., a medical technology company that develops innovative medical devices for the treatment of chronic diseases at home, announced today the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $10.00 per share.. In addition, Tactile has granted the underwriters a 30- day option to purchase up to an additional 600,000 shares of common stock at the public offering price to..."/>
Tactile Systems Announces Pricing of Initial Public Offering
Tokai Pharmaceuticals, Inc. concerning possible violations of federal securities laws. If you purchased or otherwise acquired Tokai shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you."/>
IMPORTANT INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims against Tokai Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
Alere Inc., a global leader in rapid diagnostic tests, today announced that it received a U.S. Department of Justice subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016. The subpoena seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for patient samples tested at the Company's Austin, Texas pain management laboratory."/>
Alere Comments on Pain Management Subpoena
Resverlogix Corp. announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2016. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing..."/>
Resverlogix Files 2016 Year-End Disclosure Documents
Resverlogix Corp. announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2016. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by..."/>
Resverlogix Files 2016 Year-End Disclosure Documents

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology663 Articles
Financials634 Articles
Consumer Discretionary565 Articles
Industrials404 Articles
Health Care387 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.